Drugs / Hib-MenCY-TT
last change Mar 2016 re-read 2 minutes ago

Hib-MenCY-TT

also known as MenHibrix

Vaccine

Developed for
haemophilus infectious disease · meningococcal infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01978093 Feb 2014 → Mar 2016 haemophilus infectious disease, meningococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Hib-MenCY-TT ClinicalTrials.gov intervention name — accepted as the source's own label NCT01978093
Known as MenHibrix “Biological: Hib-MenCY-TT (MenHibrix®)” NCT01978093
Modality Vaccine “Hib-MenCY-TT (MenHibrix®) vaccineNCT01978093